Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age

NCT02095314 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT02095314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02095314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age
Lead sponsor
PT Bio Farma
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2014
Completion date
December 31, 2014
Enrollment
399 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

healthy